Management of obesity-induced kidney disease: A critical review of the literature

Obesity Facts

Volumn 5, Issue 6, 2012, Pages 821-832

  Kiortsis, Dimitrios N ^a   Christou, Maria A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Albuminuria; Creatinine; Kidney disease; Obesity; Weight loss

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CREATININE; CYSTATIN C; LEPTIN; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRANSFORMING GROWTH FACTOR BETA;

AEROBIC EXERCISE; ALBUMINURIA; BARIATRIC SURGERY; CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DIET THERAPY; ENDOTHELIUM CELL; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTROPHY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; LOW CALORY DIET; LOW FAT DIET; MESANGIUM CELL; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DIET; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASCULITIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; EXERCISE; KIDNEY FUNCTION;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BIOLOGICAL MARKERS; DIET, REDUCING; EXERCISE; HUMANS; OBESITY; RENAL INSUFFICIENCY, CHRONIC; WEIGHT LOSS; WEIGHT REDUCTION PROGRAMS;

EID: 84870294965     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000345919     Document Type: Review

References (61)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Ann Intern Med 2003; 139: 137-147.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
4. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008 Jan;73(1):19-33.
5. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850.
6. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D: Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-up Program. Am J Kidney Dis 2005; 46: 587-594.
7. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28.
8. Wolf G, Ziyadeh FN: Leptin and renal fibrosis. Contrib Nephrol 2006; 151: 175-183.
9. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ: Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656.
10. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, Toutouzas P, Stefanadis C, Kallikazaros I: Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-951.
11. Lin J, Hu FB, Curhan G: Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 2007; 30: 239-244.
12. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168: 5817-5823.
13. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, Nickenig G: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534-541.
14. Zhang XL, Topley N, Ito T, Phillips A: Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem 2005; 280: 12239-12245.
15. Stuveling EM, Hillege HL, Bakker SJL, Gans ROB, de Jong PE, de Zeeuw D: C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63: 654-661.
16. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288:H2031-H2041.
17. Wahba IM, Mak RH: Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562.
18. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
19. Kambham N, Markowitz G, Valeri A, Lin J, D'Agati V: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001; 59: 1498-1509.
20. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND Study Group: Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26:S21-S24.
21. Ruggenenti P, Remuzzi G: Time to abandon microalbuminuria? Kidney Int 2006; 70: 1214-1222.
22. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K: Effect of weight loss using formula diet on renal function in obese patient with diabetic nephropathy. Int J Obes 2005; 29: 1115-1120.
23. Morales E, Valero MA, Leon M, Hernandez E, Praga M: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-327.
24. Solerte SB, Fioravanti M, Schifino N, Ferrari E: Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 1989; 13: 203-211.
25. Ohashi H, Oda H, Ohno M, Watanabe S: Weight reduction improves high blood pressure and microalbuminuria in hypertensive patients with obesity. Nihon Jinzo Gakkai Shi 2001; 43: 333-339.
26. Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL: Effects of body weight-loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70: 35-41.
27. Lazarevic G, Antic S, Vlahovic P, Djordjevic V, Zvezdanovic L, Stefanovic V: Effects of aerobic exercise on microalbuminuria and enzymuria in type 2 diabetic patients. Ren Fail 2007; 29: 199-205.
28. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC: The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162: 2428-2435.
29. Cook S, MacLaughlin H, Macdougall IC: A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic disease. Nephrol Dial Transplant 2008; 23: 263-268.
30. Cubeddu LX, Alfieri AB, Hoffmann IS: Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese normoalbuminuric non-diabetic patients. Am J Hypertens 2008; 21: 105-110.
31. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, for the OBES-002 Study Group: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes 2004; 28: 1399-1410.
32. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L; OBDM-003 Study Group: Topiramate in the treatment of obese subjects with drug-naïve type 2 diabetes. Diabetes Obes Metab 2007; 9: 360-368.
33. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486.
34. Palomar R, Fernández-Fresnedo G, Domínguez-Diez A, López-Deogracias M, Olmedo F, Martín de Francisco AL, Sanz de Castro S, Casado Martín F, Gómez-Fleitas M, Arias M, Fernández-Escalante C: Effects of weight loss after biliopancreatic diversion on metabolism and cardiovascular profile. Obes Surg 2005; 15: 794-798.
35. Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R, Alves Buriti N, Cunha Barbosa Saheb G, Rossi M: Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol 2009; 22: 637-646.
36. Navaneethan SD, Yehnert H: Bariatric surgery and progression of chronic kidney disease. Surg Obes Relat Dis 2009; 5: 662-665.
37. Schuster DP, Teodorescu M, Mikami D, Foreman K, Rogers P, Needleman BJ: Effect of bariatric surgery on normal and abnormal renal function. Surg Obes Relat Dis 2011; 7: 459-464
38. Serra A, Granada ML, Romero R, Bayés B, Cantón A, Bonet J, Rull M, Alastrue A, Formiguera X: The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr 2006; 25: 400-408.
39. Navaneethan SD, Kelly KR, Sabbagh F, Schauer PR, Kirwan JP, Kashyap SR: Urinary albumin excretion, HMW adiponectin and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg 2010; 20: 308-315.
40. Agrawal V, Krause KR, Chengelis DL, Zalesin KC, Rocher LL: Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis 2009; 5: 20-26.
41. Navarro-Díaz M, Serra A, Romero R, Bonet J, Bayés B, Homs M, Pérez N, Bonal J: Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006; 17:S213-S217.
42. Agrawal V, Khan I, Rai B, Krause KR, Chengelis DL, Zalesin KC, Rocher LL, McCullough PA: The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol 2008; 70: 194-202.
43. Saliba J, Kasim NR, Tamboli RA, Isbell JM, Marks P, Feurer ID, Ikizler A, Abumrad NN: Roux-en-Y bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery 2010; 147: 282-291.
44. Alexander JW, Goodman HR, Hawver LM, Cardi MA: Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis 2009; 5: 237-241.
45. Alexander JW, Goodman H: Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract 2007; 22: 16-21.
46. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK: Influence of excessive weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55: 1560-1567.
47. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in healthier as compared with sicker haemodialysis patients: results from the Dialysis Outcomes and Practise Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16: 2386-2394.
48. Johansen KL, Young B, Kaysen GA, Chertow GM: Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80: 324-332.
49. Beddhu S, Pappas LM, Ramkumar N, Samore MH: Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14: 2366-2372.
50. Araújo IC, Kamimura MA, Draibe SA, Canziani ME, Manfredi SR, Avesani CM, Sesso R, Cuppari L: Nutritional parameters and mortality in incident hemodialysis patients: Effect of body mass index, muscle mass and dietary intake. J Renal Nutr 2006; 16: 27-35.
51. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE: A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003; 41: 733-741.
52. Elsayed EF, Sarnak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, Levey AS, Weiner DE: Waist-to-hip ratio, body mass index and subsequent kidney disease and death. Am J Kidney Dis 2008; 52: 29-38.
53. Schmieder RE, Ruilope LM, Barnett AH: Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol 2011; 24: 569-580.
54. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S: Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1565-1574.
55. Friedman AN: High-protein diets: Potential effects on the kidney in renal health and disease. Am J Kidney Dis 2004; 44: 950-962.
56. Uribarri J, Tuttle KR: Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006; 1: 1293-1299.
57. Yancy WS, Olsen MK, Guyton JR, Bakst RP, Westman EC: A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004; 140: 769-777.
58. Brinkworth GD, Buckley JD, Noakes M, Clifton PM: Renal function following long-term weight loss in individuals with abdominal obesity on a very-low-carbohydrate diet vs high-carbohydrate diet. J Am Diet Assoc 2010; 110: 633-638.
59. de Oliveira LD, Diniz MT, de Fatima H S Diniz M, Savassi-Rocha AL, Camargos ST, Cardoso F: Rhabdomyolysis after bariatric surgery by Roux-en-Y gastric bypass: a prospective study. Obes Surg 2009; 19: 1102-1107.
60. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, Kumar R, Lieske JC: Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72: 100-107.
61. Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG: Enteric hyperoxaluria, nephrolithiasis and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1: 481-485.